Skip to main content
. 2017 Jul 5;5(1):1345580. doi: 10.1080/20016689.2017.1345580

Figure 2.

Figure 2.

(A) Changes in national eligibility criteria reported for biological disease-modifying antirheumatic drug (DMARD) reimbursement since 2011. (B) Heat map of countries according to their access scores. (C) Grouping of countries according to low, moderate, and high access composite eligibility scores (see Methods section for definitions of low, moderate, and high). (D) Population sizes of rheumatoid arthritis patients eligible for biological DMARD treatment within national criteria.